Go Deep
OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,945 | -0.8 | 0.55 | 0.01 | 223.32 |
| Oct 2026 | 22,045 | -0.7 | 0.53 | 0.01 | 213.63 |
| Oct 2026 | 22,171 | -0.7 | 0.50 | 0.01 | 202.27 |
| Oct 2026 | 22,202 | -0.7 | 0.49 | 0.01 | 198.90 |
| Oct 2026 | 22,045 | -0.7 | 0.53 | 0.01 | 213.34 |
| Oct 2026 | 21,930 | -0.8 | 0.56 | 0.01 | 223.77 |
| Oct 2026 | 21,993 | -0.8 | 0.54 | 0.01 | 217.54 |
| Oct 2026 | 21,699 | -0.8 | 0.61 | 0.01 | 243.53 |
OnKure Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -15,346,000.0 | -15,157,000.0 | -13,503,000.0 | -14,699,000.0 |
| EPS | -0.3 | -1.1 | -1.0 | -1.1 |
OnKure Therapeutics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -59,517,000.0 | -52,673,000.0 | -35,311,000.0 | -29,512,000.0 |
| EPS | -4.4 | -15.3 | -2.6 | -2.2 |
OnKure Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 62,117,000.0 | 114,907,000.0 | 35,734,000.0 | 15,999,000.0 |
| Total Liabilities | 5,933,000.0 | 11,079,000.0 | 137,576,000.0 | 70,417,000.0 |
| Total Equity | 56,184,000.0 | 103,828,000.0 | -101,842,000.0 | -54,418,000.0 |
Owes vs Owns
OnKure Therapeutics, Inc. owed $0.04 for every $1 it owned in Jun 2026, down from $4.40 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.04× | 0.10× | 0.10× | 3.85× | 4.40× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
OnKure Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 95.1%Fixed assets (tangible) 1.6%Other assets 3.3%
How it's funded — Dec 2025
Short-term debt 0.9%Payables 2.3%Other liabilities 6.4%Shareholders' equity 90.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 59.0 | 110.8 | 29.9 | 11.5 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.0 | 1.8 | 1.9 | 2.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.1 | 2.4 | 3.9 | 2.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.5 | 0.5 | 0.2 | 0.2 |
| Long-term debt | 0.0 | 0.5 | 0.5 | 0.5 |
| Payables | 1.4 | 3.0 | 3.4 | 2.5 |
| Other liabilities | 4.0 | 7.0 | 133.5 | 67.3 |
| Shareholders' equity | 56.2 | 103.8 | -101.8 | -54.4 |
| Net tangible assets | 56.2 | 103.8 | -101.8 | -54.4 |
OnKure Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -51,828,000.0 | -51,117,000.0 | -34,546,000.0 | -26,953,000.0 |
| Investing Activities | -46,000.0 | 15,873,000.0 | -246,000.0 | -1,134,000.0 |
| Financing Activities | 163,000.0 | 116,129,000.0 | 53,125,000.0 | 26,465,000.0 |